1. Rumgay H, Arnold M, Ferlay J, et al. Global burden of primary liver cancer in 2020 and predictions to 2040. J Hepatol 2022; 77: 1598-1606.
2.
Ahn JC, Lee YT, Agopian VG, et al. Hepatocellular carcinoma surveillance: current practice and future directions. Hepatoma Res 2022; 8: 10.
3.
Harris PS, Hansen RM, Gray ME, et al. Hepatocellular carcinoma surveillance: An evidence-based approach. World J Gastroenterol 2019; 25: 1550-1559.
4.
El-Houseini ME, Ismail A, Abdelaal AA, et al. Role of TGF-β1 and C-kit mutations in the development of hepatocellular carcinoma in hepatitis C virus-infected patients: in vitro study. Biochemistry (Mosc) 2019; 84: 941-953.
5.
Herrera-López EE, Guerrero-Escalera D, Aguirre-Maldonado I, et al. Annexins A2 and A5 are potential early biomarkers of hepatocarcinogenesis. Sci Rep 2023; 13: 6948.
6.
Sun Y, Gao G, Cai J, et al. Annexin A2 is a discriminative serological candidate in early hepatocellular carcinoma. Carcinogenesis 2013; 34: 595-604.
7.
Grindheim AK, Saraste J, Vedeler A. Protein phosphorylation and its role in the regulation of Annexin A2 function. Biochim Biophys Acta Gen Subj 2017; 1861 (11 Pt A): 2515-2529.
8.
Tas F, Tilgen Yasasever C, Karabulut S, et al. Circulating annexin A2 as a biomarker in gastric cancer patients: correlation with clinical variables. Biomed Pharmacother 2015; 69: 237-241.
9.
Lokman NA, Ween MP, Oehler MK, et al. The role of annexin A2 in tumorigenesis and cancer progression. Cancer Microenviron 2011; 4: 199-208.
10.
Shaker MK, Abdel Fattah HI, Sabbour GS, et al. Annexin A2 as a biomarker for hepatocellular carcinoma in Egyptian patients. World J Hepatol 2017; 9: 469-476.
11.
Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol 2022; 76: 681-693.
12.
Gao Y, Lyu L, Feng Y, et al. A review of cutting-edge therapies for hepatocellular carcinoma (HCC): Perspectives from patents. Int J Med Sci 2021; 18: 3066-3081.
13.
Volk ML, Hernandez JC, Su GL, et al. Risk factors for hepatocellular carcinoma may impair the performance of biomarkers: a comparison of AFP, DCP, and AFP-L3. Cancer Biomark 2007; 3: 79-87.
14.
Park HJ, Kim SY. Imaging modalities for hepatocellular carcinoma surveillance: Expanding horizons beyond ultrasound. J Liver Cancer 2020; 20: 99-105.
15.
Xu XH, Pan W, Kang LH, et al. Association of annexin A2 with cancer development (Review). Oncol Rep 2015; 33: 2121-2128.
16.
Shang S, Plymoth A, Ge S, et al. Identification of osteopontin as a novel marker for early hepatocellular carcinoma. Hepatology 2012; 55: 483-490.
17.
Elgezawy E, Khalaf M, Eldeen M, et al. P-022 Expression of circulating annexin A2 in hepatic diseases and hepatocellular carcinoma. Ann Oncol 2015; 26: iv6.
18.
Galle PR, Foerster F, Kudo M, et al. Biology and significance of alpha-fetoprotein in hepatocellular carcinoma. Liver Int 2019; 39: 2214-2229.
19.
Marrero JA, Feng Z, Wang Y, et al. Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology 2009; 137: 110-118.
20.
Hanno AEFF, Abd El-Aziz FM, Deghady AA, et al. Role of annexin A2 and osteopontin for early diagnosis of hepatocellular carcinoma in hepatitis C virus patients. Egyp Liver J 2019; 9: 5.
21.
Chi X, Jiang L, Yuan Y, et al. A comparison of clinical pathologic characteristics between alpha-fetoprotein negative and positive hepatocellular carcinoma patients from Eastern and Southern China. BMC Gastroenterol 2022; 22: 202.
22.
Ibrahim A, Hashem M, Mostafa E, et al. Annexin A2 versus Afp as an efficient diagnostic serum marker for hepatocellular carcinoma. J Gastroenterol Hepatol Res 2013; 2: 780-785.
23.
Zhang HJ, Yao DF, Yao M, et al. Expression characteristics and diagnostic value of annexin A2 in hepatocellular carcinoma. World J Gastroenterol 2012; 18: 5897-5904.
24.
Liu Z, Ling Q, Wang J, et al. Annexin A2 is not a good biomarker for hepatocellular carcinoma in cirrhosis. Oncol Lett 2013; 6: 125-129.
25.
Chen CY, Lin YS, Chen CH, et al. Annexin A2-mediated cancer progression and therapeutic resistance in nasopharyngeal carcinoma. J Biomed Sci 2018; 25: 30.
26.
Mahdi AF, Malacrida B, Nolan J, et al. Expression of annexin A2 promotes cancer progression in estrogen receptor negative breast cancers. Cells 2020; 9: 1582.
27.
Gomaa A, Gomaa M, Allam N, Waked I. Hepatitis C elimination in Egypt: Story of success. Pathogens 2024; 13: 681.
28.
Kamal A, Mohsin AK, Matta C, et al. Tolloid-like 1 gene variant rs17047200, pretreatment FIB-4, ALBI and PALBI scores as predictors of hepatocellular carcinoma occurrence after directly acting antivirals. Clin Exp Hepatol 2022; 8: 330-334.
Copyright: © Clinical and Experimental Hepatology. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0). License (http://creativecommons.org/licenses/by-nc-sa/4.0/) enables reusers to distribute, remix, adapt, and build upon the material in any medium or format for noncommercial purposes only, and only so long as attribution is given to the creator. If you remix, adapt, or build upon the material, you must license the modified material under identical terms.
